Pancreatic Cancer Research

ResearcherHarbin Medical UniversityActive in the last 2 years

Guanqun Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3910-2333; OpenAlex author ID A5088685496. Sources: OpenAlex.

Their work

Papers
8
Trials
0
Grants
0
Labs led
0
Collaborators
28
Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: none · 2021: 2 papers · 2022: none · 2023: 3 papers · 2024: none · 2025: none · 2026: 2 papers

Papers 8

  1. Tumour-infiltrating adipocyte-derived 12,13-DiHOME subverts CD8+ T cell immunity in pancreatic ductal adenocarcinoma by promoting PPARγ-mediated ferritinophagy… Co-author DOI 10.1136/gutjnl-2025-337119↗
  2. Spatial Multiomics Analyses Reveal That Diabetes Promotes Pancreatic Cancer Progression by Stimulating Cholesterol-Induced Neutrophil Extracellular Trap Format… Co-author DOI 10.1158/0008-5472.can-25-2854↗
  3. Tumor Cell Derived Lnc-FSD2-31:1 Contributes to Cancer-Associated Fibroblasts Activation in Pancreatic Ductal Adenocarcinoma Progression through Extracellular … Co-author DOI 10.1002/advs.202203324↗
  4. circEIF3I facilitates the recruitment of SMAD3 to early endosomes to promote TGF-β signalling pathway-mediated activation of MMPs in pancreatic cancer. Co-author DOI 10.1186/s12943-023-01847-2↗
  5. Caprin-1 influences autophagy-induced tumor growth and immune modulation in pancreatic cancer. Co-author DOI 10.1186/s12967-023-04693-4↗
  6. Cancer-Associated Fibroblast (CAF) Heterogeneity and Targeting Therapy of CAFs in Pancreatic Cancer. Co-author DOI 10.3389/fcell.2021.655152↗
  7. Beneficial Diets and Pancreatic Cancer: Molecular Mechanisms and Clinical Practice. Co-author DOI 10.3389/fonc.2021.630972↗
  8. MiR-361-3p regulates ERK1/2-induced EMT via DUSP2 mRNA degradation in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41419-018-0839-8↗

Closest collaborators

The 25 strongest of 28 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jisheng Hu · 7 shared papers, 2018–2026 · strength 1.09
  2. Yongwei Wang · 6 shared papers, 2018–2026 · strength 0.87
  3. Rui Kong · 5 shared papers, 2018–2026 · strength 0.82
  4. Bei Sun · 5 shared papers, 2021–2026 · strength 0.77
  5. Hongze Chen · 6 shared papers, 2018–2023 · strength 0.76
  6. Wenbo Yang · 5 shared papers, 2021–2023 · strength 0.69
  7. Yan Luo · 3 shared papers, 2023–2026 · strength 0.60
  8. Xinglong Geng · 4 shared papers, 2021–2023 · strength 0.54
  9. Gang Wang · 3 shared papers, 2023–2026 · strength 0.53
  10. Le Li · 3 shared papers, 2021–2026 · strength 0.52
  11. Chundong Cheng · 3 shared papers, 2021–2023 · strength 0.41
  12. Zhongjie Zhao · 3 shared papers, 2021–2023 · strength 0.41
  13. Le Li · 3 shared papers, 2018–2023 · strength 0.36
  14. Yangyang Zhang · 2 shared papers, 2023 · strength 0.28
  15. Danxi Liu · 2 shared papers, 2023 · strength 0.28
  16. Tao Zhang · 2 shared papers, 2021–2023 · strength 0.27
  17. Bei Sun · 2 shared papers, 2018–2023 · strength 0.23
  18. X W Bai · 1 shared paper, 2026 · strength 0.22
  19. Xinyuan Liu · 1 shared paper, 2026 · strength 0.22
  20. Yingmei Zhang · 1 shared paper, 2026 · strength 0.22
  21. Bo Sun · 1 shared paper, 2026 · strength 0.22
  22. Liwei Liu · 1 shared paper, 2023 · strength 0.15
  23. Zengfu Song · 1 shared paper, 2023 · strength 0.14
  24. Shangha Pan · 1 shared paper, 2023 · strength 0.14
  25. Xuewei Bai · 1 shared paper, 2023 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.